ACTR-70. IMPACT OF BEVACIZUMAB IN PATIENTS WITH RECURRENT GLIOBLASTOMA AND POOR PERFORMANCE STATUS

Clinical trials have showed that bevacizumab is beneficial for patients with recurrent glioblastoma and partially effective against newly diagnosed glioblastoma. However, glioblastoma patients with poor performance status (PS) were excluded from these clinical trials, and the efficacy of bevacizumab...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:Neuro Oncol
Auteurs principaux: Furuse, Motomasa, Kawabata, Shinji, Ikeda, Naokado, Nonoguchi, Naosuke, Tamura, Yoji, Kajimoto, Yoshinaga, Miyatake, Shin-Ichi, Kuroiwa, Toshihiko
Format: Artigo
Langue:Inglês
Publié: Oxford University Press 2017
Sujets:
Abstracts
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC5693094/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/nox168.057
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires